PubMed Health⌕ Search

Biomedical subjects

F C McDuffie

Publications and source records attributed to F C McDuffie.

At least 19 recordsLinked to original sources

The use of long-acting drugs in the treatment of rheumatoid arthritis.

Experience to date strongly indicates that long-acting drugs currently used in treatment of rheumatoid arthritis are very potent antiinflammatory agents which act in most cases by completely unknown mechanisms. All of them have built in but recognizable toxicity which can usually be prevented by appropriate monitoring. Although most of them offer relatively short term (up to 3 years) benefits, with the probable exception of methotrexate, nonetheless they can offer for a period of time improved function and relief of pain for many individuals. Thus, even though they do not dramatically affect the long-range outcome of the disease, they continue to offer useful benefit for patients with rheumatoid arthritis who are not responding to conservative therapy. Some of the long-acting agents are only slightly more toxic than the widely nonsteroidal antiinflammatory drugs which do have a definite risk of serious upper gastrointestinal bleeding. Currently the use of combinations as well as the continued introduction of new drugs in this class, offer hope that greater benefit than we can currently provide is within reach over the next few years.

Anti-Inflammatory Agents↗

Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States.

The National Arthritis Data Workgroup focused its studies primarily on joint disease with the addition of osteoporosis which is a frequently occurring musculoskeletal condition and public health problem. We used national data sets as well as published studies to estimate prevalence in the United States. We report on prevalence rather than incidence because of the difficulty in defining the point of onset and because primary national data sources currently available are concerned with disease prevalence.

Adolescent↗

The role of the Arthritis Foundation in training of rehabilitation research manpower.

In 1973 the Arthritis Foundation established a research training program for nonphysician health professionals in fields related to nonmedicinal care such as physical therapy, occupational therapy, psychology and health education. This program is primarily designed for individuals performing the research involved in a predoctoral program. For trained investigators in this field the Foundation offers a research grants program as well.

Arthritis↗

Antigen detection in immune complexes by a modified staphylococci binding assay and Western blot analysis.

The combination of a modified Staphylococci binding assay for immune complexes and Western blot analysis is described for the isolation and detection of antigen in immune complexes from human sera. The strategy of the procedure is to preclear immune complexes from other serum components by sequential polyethylene glycol precipitation and incubation with insoluble protein A under conditions in which immune complexes are preferentially bound. Immune complexes are eluted from protein A in sodium dodecyl sulfate buffer and dissociated by acrylamide electrophoresis. Resolved proteins are then transblotted to nitrocellulose, and antigen is detected with specific antibody. Immune complexes were prepared in vitro with an antigen (keyhole limpet hemocyanin) that focuses well on electrophoresis and for which a potent immunologic probe (antibody) was available. In this system, antigen could be detected when immune complexes were present in sera in concentrations as low as 20 micrograms aggregated-IgG eq/ml, regardless of antigen-antibody ratio. We demonstrate the detection of horse globulin in immune complexes from a patient with acute serum sickness and hepatitis B virus antigen in complexes from a patient with vasculitis.

Adult↗

Morbidity impact of rheumatoid arthritis on society.

Classic and definite rheumatoid arthritis affects from 0.5 to 1 percent of the United States' population between the ages of 20 and 80. In the age group of 55 to 75 years, this figure increases to 4.5 percent. In addition to the pain and suffering produced by this disease, family structure is dramatically affected--the divorce rate for patients with rheumatoid arthritis is 70 percent above that for the general population. Rheumatoid arthritis also results in serious economic loss to society. In 1983, the direct cost (out-of-pocket expense for medical care) was $777 million, and the indirect cost (loss of productivity) was $215 million, with a total of approximately $1 billion. The average person with stage III rheumatoid arthritis suffers a 60 percent decline in earnings during the first six years after onset of the disease. Recent studies have indicated that the ability to remain employed depends at least as much on job-related factors as on the extent of disease or success of medical treatment. Job autonomy or the ability to control one's working conditions is the most important factor. Other important variables are education, seniority, and work that is not excessively physically demanding. Good transportation between home and job is also an essential requirement for remaining employed. There are few data available on the cost/benefit ratio of the treatment of rheumatoid arthritis. An 18-month study showed a trend toward greater improvement in patients given optimal care by a team of experts in a medical center as compared with average treatment provided in the community. A study in Scotland on cost of hospitalization of 366 patients (about one half underwent surgery) showed cost benefits of xi 14,000 to xi 131,000 over a five- to 10-year period for those who returned to work. Patients who did not return to work incurred medical costs of xi 100,000. There is little question that more effective medical treatment and better rehabilitation strategies for people with rheumatoid arthritis would provide significant benefits for patients, their families, and society.

Adolescent↗

Immunoassay for IgG rheumatoid factor with a murine monoclonal anti-Fd antibody.

Conventional radioimmunoassays for IgG rheumatoid factors (RF) detect the binding of IgG RF (or their F(ab')2 fragments) to solid-phase human IgG Fc fragments or rabbit IgG. Binding is detected with a radiolabeled antibody that is IgG-specific but is nonreactive with human Fc (i.e., an alpha-Fd reagent) or with rabbit IgG. Anti-Fd reagents are quite laborious to produce. We developed a murine monoclonal alpha-Fd antibody, confirmed its specificity, and compared it with conventional rabbit alpha-Fd in the IgG RF radioimmunoassay. We also adapted the assay to an enzyme-linked assay with both human Fc and rabbit IgG as antigen. We compared the four assay methods with each other and examined their relationship to certain clinical and laboratory features of rheumatoid arthritis.

Animals↗

An attempt to predict the response to gold therapy in rheumatoid arthritis.

In 54 rheumatoid arthritis patients undergoing conventional chrysotherapy, we prospectively sought predictors of response, using strict clinical and laboratory criteria of improvement. Forty-five patients who completed 6-12 months of therapy were classified into 3 outcome categories: group 0, not significantly improved (18 patients); group 1, improved (18 patients); and group 2, markedly improved (9 patients). Sixty-two entry variables were tested in univariate and multivariate analysis for predictor function. No continuous variable was predictive. The discrete variables HLA-A3 positivity and HLA-DR4 negativity were the best predictors of response to gold. In a multivariate analysis using these 2 univariates (A3 and DR4) plus hemoglobin, we developed a discriminant function that correctly predicted outcome in 21 of 23 patients in groups 0 and 2. We also observed that of 15 DR blank patients (10 of whom were DR4 blank), none entered remission.

Arthritis, Rheumatoid↗

Interaction of human platelets with particle-adherent aggregated IgG: description of the experimental system and role of C1q and monomeric IgG.

We describe a system for studying the interaction of human, single donor platelets and aggregated human IgG adherent to erythrocyte stroma (ES/Agg IgG) and report the role of monomeric IgG and C1q in this interaction. Monomeric IgG inhibits platelet aggregation by the ES/Agg IgG and acts on the platelet surface. Complement components inhibit the aggregation of platelets by the ES/Agg IgG, and C1q is necessary but not sufficient for this inhibition. Complement components act on the ES/Agg IgG. The platelet Fc receptor does not consist solely of divalent cation-dependent complement components.

Blood Platelets↗

Comparison of clinical and serologic markers in systemic lupus erythematosus and overlap syndrome: a review of 247 patients.

To evaluate the relationship between clinical manifestations and serologic markers in patients with systemic lupus erythematosus (SLE) and patients with an overlap syndrome, we reviewed the charts of 247 such patients who had been examined between 1975 and 1979. All patients with an overlap syndrome had a high frequency of arthritis and Raynaud's phenomenon and a low frequency of renal disease regardless of the presence or absence of antibody to nuclear ribonucleoprotein (anti-nRNP) and antibody to Sm antigen (anti-Sm). The presence or absence of anti-nRNP and anti-Sm did not distinguish whether a patient had SLE or an overlap syndrome and could not be used to predict clinical manifestations of disease.

Antigens, Nuclear↗